Immuno Research Inc. (formerly Biothera Inc.) was established in 1997 to develop carbohydrate immune modulators for a wide range of potential applications, including pharmaceuticals and ingredients with immune-support benefits for foods, beverages and supplements and animal health and nutrition products.
The company has amassed world-class expertise in yeast beta 1,3/1,6 glucans, and has created an extraordinary technology platform for engaging and directing the innate and adaptive immune responses with the potential to prevent and treat disease. Immuno Research’s technology is protected by more than 100 patents and patents pending.
Immuno Research has successfully commercialized specific aspects of our technology through exclusive licensing agreements with a pharmaceutical company in phase 2 clinical development of cancer immunotherapies and a global food and ingredient company.
In 2016, Biothera Inc. was spun off as an independent company from Biothera Holding Corp. (and its subsidiary Biothera Pharmaceuticals Inc.) and changed its name to Immuno Research Inc. Our management team and board combine extensive experience of the development and commercialization of beta-glucans with many years of successful research, operations, management and sales and marketing experience.